TGFB1 and neoplasm: Indeed, a recent study has shown that lack of response to atezolizumab (anti-PD-L1 mAb) in metastatic urothelial cancer patients was associated with active TGF-β signaling in peritumoral stroma and especially in patients with T cells excluded from the tumor parenchyma [27].